Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | CD274 pos STK11 mut |
| Therapy | unspecified PD-1 antibody |
| Indication/Tumor Type | lung non-small cell carcinoma |
| Response Type | predicted - resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| CD274 pos STK11 mut | lung non-small cell carcinoma | predicted - resistant | unspecified PD-1 antibody | Clinical Study - Cohort | Actionable | In a clinical study, non-small cell lung carcinoma patients positive for CD274 and harboring an STK11 mutation treated with a PD-1 inhibitor demonstrated a lower objective response rate compared to CD274-positive patients with wild-type STK11, 0% (0/11) vs 34.5% (19/55), respectively (PMID: 29773717). | 29773717 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29773717) | STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma. | Full reference... |